Comparable stake leader
Raza Bokhari
SEC ownership of Medicus Pharma Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001997296.
Disclosed value leader
VELOCITY FUND PARTNERS, LP
Comparable rows
5/43
Latest evidence
30 Sep 2026
- Public ticker
- MDCX, MDCXW on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Raza Bokhari
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
5 of 43
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Raza Bokhari
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001997296
- Issuer location
- W. Conshohocken, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Medicus Pharma Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Raza Bokhari
Disclosed value leader
VELOCITY FUND PARTNERS, LP
Comparable rows
5/43
Latest evidence
30 Sep 2026
3/4/5
13D/G
13F
Lead comparable stake: 5.3%
38 rows are not safely comparable across share classes.
13D/G row: Raza Bokhari
Showing 1-8 of 43 holder rows.
Quick read
Raza Bokhari leads the comparable SEC ownership view at 5.3%.
5 of 43 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Raza Bokhari's linked filing trail.
Comparable ownership
Top 5
Raza Bokhari
5.3%
ARMISTICE CAPITAL, LLC
5%
John Jason Hathaway
4.5%
Ajay Raju
3.7%
Kenneth R. Melani
3.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 43 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Raza Bokhari |
3/4/5
13D/G
Chief Executive Officer, Director · BOKHARI, RAZA
|
5.3%
Reported 13D/G
· 04 Sep 2026
|
$2,060,146
4,234,349 shares
mixed-class rows
|
— | 04 Sep 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
5%
Reported 13D/G
· 30 Jun 2025
|
$2,835,244
935,724 shares
|
-$1,000,736 | 30 Jun 2025 |
| John Jason Hathaway |
13D/G
John Hathaway
|
4.5%
Reported 13D/G
· 30 Jun 2025
|
$2,426,885
800,952 shares
|
$0 | 30 Jun 2025 |
| Ajay Raju |
13D/G
3/4/5
Raju Ajay · Director
|
3.7%
Reported 13D/G
· 31 Mar 2026
|
$893,750
2,031,250 shares
|
+$13,750 | 31 Mar 2026 |
| Kenneth R. Melani |
13D/G
3/4/5
Melani Kenneth R. · 10%+ Owner
|
3.6%
Reported 13D/G
· 30 Sep 2026
|
—
3,248,741 shares
|
$0 | 30 Sep 2026 |
| VELOCITY FUND PARTNERS, LP |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$38,572,068
6,572,482 shares
mixed-class rows
|
— | 20 May 2025 |
| James P. Quinlan |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$903,404
274,147 shares
mixed-class rows
|
— | 13 Aug 2025 |
| Carolyn F. Bonner |
3/4/5
President and CFO
|
—
mixed-class rows
|
$814,260
1,739,493 shares
mixed-class rows
|
— | 04 Sep 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 03 Nov 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Medicus Pharma Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
VELOCITY FUND PARTNERS, LP
Net 12M change
$0
Latest report
04 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| VELOCITY FUND PARTNERS, LP | 10%+ Owner | $38,572,068 | Mixed | 20 May 2025 | ||
| Raza Bokhari | Chief Executive Officer, Director | $2,060,146 | Mixed | 04 Sep 2026 | ||
| James P. Quinlan | Chief Financial Officer | $903,404 | Mixed | 13 Aug 2025 | ||
| Carolyn F. Bonner | President and CFO | $814,260 | Mixed | 04 Sep 2026 | ||
| Faisal Mehmud | Chief Medical Officer | $805,823 | Mixed | 04 Sep 2026 | ||
| Edward J. Brennan | Chief Scientific Officer | $450,634 | Mixed | 04 Sep 2026 | ||
| Andrew A. Smith | Chief Operating Officer | $328,234 | Mixed | 04 Sep 2026 | ||
| Barry Fishman | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| Sara R. May | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| William L. Ashton | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| Larry Kaiser | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| Robert J. Ciaruffoli | Director | $74,750 | Mixed | 03 Jun 2026 | ||
| Patrick J. Mahaffy | Director | $74,413 | Mixed | 03 Jun 2026 | ||
| Ajay Raju | Director | Mixed | 03 Jun 2026 | |||
| Cathy McMorris Rodgers | Director | Mixed | 03 Jun 2026 | |||
| Frank W. Lavelle | Director | Mixed | 31 Dec 2024 | |||
| Kenneth R. Melani | 10%+ Owner | Mixed | 31 Dec 2024 |
Recent insider transactions for Medicus Pharma Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Andrew A. Smith | MDCX | Common Shares, no par value | Award | 448350% | 735,294 | 735,458 | 04 Sep 2026 | Direct | ||
| Andrew A. Smith | MDCX | Stock Option (right to buy) | Award | 125,000 | 125,000 | 04 Sep 2026 | Direct | |||
| Faisal Mehmud | MDCX | Common Shares, no par value | Award | 1,470,588 | 1,470,588 | 04 Sep 2026 | Direct | |||
| Faisal Mehmud | MDCX | Stock Option (right to buy) | Award | 250,000 | 250,000 | 04 Sep 2026 | Direct | |||
| Edward J. Brennan | MDCX | Common Shares, no par value | Award | 680% | 588,235 | 674,735 | 04 Sep 2026 | Direct | ||
| Edward J. Brennan | MDCX | Stock Option (right to buy) | Award | 100,000 | 100,000 | 04 Sep 2026 | Direct | |||
| Carolyn F. Bonner | MDCX | Common Shares, no par value | Award | 7778.8% | 1,470,588 | 1,489,493 | 04 Sep 2026 | Direct | ||
| Carolyn F. Bonner | MDCX | Stock Option (right to buy) | Award | 250,000 | 250,000 | 04 Sep 2026 | Direct | |||
| Raza Bokhari | MDCX | Common Shares, no par value | Award | 2,941,176 | 2,941,176 | 04 Sep 2026 | Direct | |||
| Raza Bokhari | MDCX | Stock Option (right to buy) | Award | 500,000 | 500,000 | 04 Sep 2026 | Direct | |||
| Andrew A. Smith | MDCX | Stock Option (right to buy) | Award | 200,000 | 200,000 | 03 Jun 2026 | Direct | |||
| Cathy McMorris Rodgers | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Ajay Raju | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Faisal Mehmud | MDCX | Stock Option (right to buy) | Award | 250,000 | 250,000 | 03 Jun 2026 | Direct | |||
| Sara R. May | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Patrick J. Mahaffy | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Larry Kaiser | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Barry Fishman | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Robert J. Ciaruffoli | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Edward J. Brennan | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 03 Jun 2026 | Direct | |||
| Carolyn F. Bonner | MDCX | Stock Option (right to buy) | Award | 250,000 | 250,000 | 03 Jun 2026 | Direct | |||
| Raza Bokhari | MDCX | Stock Option (right to buy) | Award | 500,000 | 500,000 | 03 Jun 2026 | Direct | |||
| William L. Ashton | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 03 Jun 2026 | Direct | |||
| Andrew A. Smith | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 30 Mar 2026 | Direct | |||
| Cathy McMorris Rodgers | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Ajay Raju | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Faisal Mehmud | MDCX | Stock Option (right to buy) | Award | 125,000 | 125,000 | 30 Mar 2026 | Direct | |||
| Sara R. May | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Patrick J. Mahaffy | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Larry Kaiser | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Barry Fishman | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Robert J. Ciaruffoli | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Edward J. Brennan | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Carolyn F. Bonner | MDCX | Stock Option (right to buy) | Award | 100,000 | 100,000 | 30 Mar 2026 | Direct | |||
| Raza Bokhari | MDCX | Stock Option (right to buy) | Award | 325,000 | 325,000 | 30 Mar 2026 | Direct | |||
| William L. Ashton | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 30 Mar 2026 | Direct | |||
| Andrew A. Smith | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 16 Dec 2025 | Direct | |||
| Cathy McMorris Rodgers | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Ajay Raju | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Faisal Mehmud | MDCX | Stock Option (right to buy) | Award | 75,000 | 75,000 | 16 Dec 2025 | Direct | |||
| Sara R. May | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Patrick J. Mahaffy | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Larry Kaiser | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Barry Fishman | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Robert J. Ciaruffoli | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct | |||
| Edward J. Brennan | MDCX | Stock Option (right to buy) | Award | 50,000 | 50,000 | 16 Dec 2025 | Direct | |||
| Carolyn F. Bonner | MDCX | Stock Option (right to buy) | Award | 75,000 | 75,000 | 16 Dec 2025 | Direct | |||
| Raza Bokhari | MDCX | Stock Option (right to buy) | Award | 125,000 | 125,000 | 16 Dec 2025 | Direct | |||
| William L. Ashton | MDCX | Stock Option (right to buy) | Award | 25,000 | 25,000 | 16 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.